HAS Group

Corporate Presentation

HAS Healthcare Advanced Synthesis

cerbios

Building upon a solid portfolio of established **APIs** and **Corporate products**, the HAS Group has become an integrated and complementary **leader in the CDMO space** specialized in **APIs, HPAPIs, Anticancer, Linker-Payloads and ADCs**, from early phase development to commercial supply.

HAS Healthcare Advanced Synthesis

cerbios

The HAS Group

Headquarters and **production sites** in **Switzerland**, plus a U.S. based entity, to ensure a **global presence** of the Group

Manufacturing sites in Switzerland

1. Biasca, Ticino – **HAS Healthcare Advanced Synthesis SA**
2. Barbengo (Lugano),Ticino – **Cerbios-Pharma SA**
3. Couvet, Neuchâtel – **GMT Fine Chemicals SA**

U.S. Entity

- Delaware, USA – **HAS Synthesis LLC**

HAS Healthcare Advanced Synthesis

cerbios

Manufacturing and Development Sites

HAS Healthcare Advanced Synthesis SA

Biasca, Switzerland

The site in **Biasca** is fully **devoted to CDMO services**, fully structured from development to manufacture of classic Active Pharmaceutical Ingredients (**APIs**), cGMP Advanced Intermediates, High Potency APIs (**HPAPIs**) and **Anticancer compounds** from clinical to commercial supply

Cerbios-Pharma SA

Barbengo (Lugano), Switzerland

Cerbios plant in **Lugano** is fully integrated for the development and manufacturing of **APIs** (Chemical and Biologicals) **HPAPI's** and **ADCs**. The site also hosts an R&D center of excellence for ADCs

GMT Fine Chemicals SA

Couvet (Neuchâtel), Switzerland

GMT is a manufacturing site in **Couvet** dedicated to the production of **Reduced Folates** sold worldwide

History & Milestones

1980s
- Construction of Helsinn Chemicals SA in Biasca

1990s
- Extension of chemical labs and building of finished products and packaging warehouse
- 1st USA FDA Audit

2000s
- ISO14001 Certification Extension of Chemicals Labs
- Construction of new building and opening of HAS
- New Operating Unit HAS

2010s
- Office buildings extension and restructuring of facilities and opening of new **Anticancer** Unit
- Construction of the new anticancer unit and laying of the Heating System (Termodotto)

2020s
- Completed on May 2020 the new larger scale Anticancer Production Unit
- January 2022: Launch as an independent business

HAS Healthcare Advanced Synthesis

May 2025
HAS Acquires Cerbios-Pharma SA with New Minority Shareholders 65 EP

January 2026
2nd ADC Suite (≤ 10 Kg)

1970s
- Foundation of Bioferment SA and Cernitin SA at Lugano
- Foundation of SAPEC SA at Lugano

1990s
- Start of HPAPI Operation
- Merge of Cernitin SA, Bioferment SA and Sapec SA and Foundation of Cerbios-Pharma SA

cerbios

2010s
- HPAPI Capacity increased up to 2 kg
- Acquisition of GMT Fine Chemicals SA
- New R&D Center
- Establishment of **Proveo™**, a division of Cerbios-Pharma SA, for offering an end-to-end CDMO service for ADCs
- Construction and opening of 1st ADC Suite

2020s
- Doubling R&D and Analytical Capacities for CDMO and ADC Business
- Additional HiPo Units with 2 independent Manufacturing lines for L-P(≤ 4 Kg)

LAST INVESTMENTS
- CHF 150M invested in the last 10 years
- CHF 100M investments plan in the next 5 years

HAS Healthcare Advanced Synthesis

cerbios

Fact Sheet – The Group

HAS Healthcare Advanced Synthesis

cerbios

gmt

3
Manufacting Sites in Switzerland

50y
of experience

425
Employees

2
R&D Centers

ADCs
Center of Excellence

Expertise
in chemical and biotech for top-tier CDMO services, specializing in HPAPIs, oncology, and ADCs

Experience
from early phase to process scale up

>60
countries presence

Integrated and Complementary Leader

1. A **CDMO** with a technology platform focused on **high containment** practice and **high quality**, offering services and products to **Pharma and Biotech companies** worldwide for **almost 50 years**
2. A strong market presence, with a diversified portfolio and solid financial results. The offer includes **R&D process and analytical development, CMC, small and large scale manufacturing, commercial supply** for API, HPAPI, oncology products, Linker-Payload and ADCs
3. High growth potential thanks to an extensive customer base, **continuous investments in new technologies and capacity**, and an integrated platform for the development and manufacturing of ADCs. Extensive chemical and biological know-how
4. A strong BD team acting globally, **close to our clients** from the head office in Lugano and an office in USA
5. **An efficient and validated supply chain system**, integrated internally and externally – manufacturing in 3 different plants with synergies in terms of technologies and capacity
6. A highly experienced management team **supported by > 425 passionate people**
7. Committment **to the best EHS practices** and a long lasting experience supporting a **sustainable growth**

HAS Healthcare Advanced Synthesis

cerbios

Executive Committee

Waldo Mossi
HAS-Cerbios CEO & The HAS Group CEO

Denis Angioletti
Head of Business Development & Commercial

Christian Bacilieri
Head of R&D

Peter Manini
Head of Operations

Claudio Pozzoli
Operations & R&D

Raul Riva
Head of Quality & Regulatory

Annalisa Ghielmetti
Head of Human Resources

HAS Healthcare Advanced Synthesis

cerbios

Quality: As a Service

- The high standard of our **Quality Standards and GMP compliance** is demonstrated by the track record of **FDA inspections (no 483)** at any of the sites and by the feedback from auditors of many international pharmaceutical companies that perform **GMP audits** to our **Facilities** and **Quality System**
- The **Policy** of the Quality System is based on **Product Safety**, orientation to Quality, **High Ethical Standards** and **Training** and **Awareness**
- The philosophy of the Quality & Regulatory Division has always been based on **transparency** and **open communication** with our **Partners** and **Regulatory Bodies**
- We prefer to work in **partnership** with our **Partners' Quality Units**, building relationships based on **mutual trust**.
- We like to work with our Quality Unit colleagues as one team in continuous communication taking all the key decisions together

AUTHORIZED BY:

FDA · KFDA · Pmda · ANVISA · EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH · swissmedic · Agroscope · SQS

HAS Healthcare Advanced Synthesis · cerbios

Safety: is Paramount to our Operations

Ensuring **Safe Working Conditions** is top priority at **HAS** and **Cerbios** – with long term experience in handling HPAPI

Certifications

ISO 14001 and ISO 45001 at Biasca Site

Training

Continuous personnel training and application of SOPs

Equipment

State-of-the-art isolators and containment equipment

Waste Management

Chemical separation and biological dosage (T, pH)

HAS Healthcare Advanced Synthesis

cerbios

Sustainability: Certifications and ESG initiatives

Sustainability is now a crucial focus for the pharmaceutical industry and our Group. Our numerous initiatives and investments underscore our commitment to a sustainable future.

Biasca:
Ecovadis Gold certified for the **Fourth Time** in a row

Lugano:
Ecovadis Commited

Ecovadis Evaluation Criteria:
- Environment
- Labor and Human Rights
- Ethics
- Sustainable Procurement

Carbon Neutral
According to ISO 14064-1
Year 2023
www.climate-services.ch

Carbon Neutral since 2021. HAS certified after a 10-year program to decarbonize its value chain

UN Global Compact Member (UNGC) since 2023.UNGC supports global companies that are committed to responsible business practices in the areas of human rights, labor, the environment, and corruption

Publication of the Sustainability Report 2022 according to GRI standards.
Cerbios' 2025 Sustainability Report showing EGS accomplishment over the past three years and the strategy for the future

Sustainability Report since 2012

Obtained a **score B SME** from the CDP (formerly Carbon Disclosure Project) in the category 'Climate Change'

HAS Healthcare Advanced Synthesis

cerbios

Your CDMO Expert

APIs
HPAPIs
Anticancer
Linker-Payloads
ADCs

Products

Reduced Folates
Vitamin D Derivates
Tiotropium
Isotretinoin
Probiotics
Animal Health Products

HAS Healthcare Advanced Synthesis

cerbios

Your
Contract
Development
Manufacturing
Organization
Expert

Offering the Best CDMO Standards to our Biopharmaceutical Clients

Research, Development and CMC Services

Active Pharmaceutical Ingredients (APIs)

High Potency APIs (HPAPIs)

ADCs and Anticancer Compounds

- We offer a full range of **high-quality**, **exclusive**, **personalized solutions** to our clients
- We're passionate about **tailoring our services** to our clients' **clinical and commercial manufacturing** needs
- Our services go beyond manufacturing by supporting our clients with their **analytical and regulatory requirements**
- **Containment technology** for HPAPIs, ADCs and anticancer compounds
- Specializing in the delivery of APIs for **target therapies**, **oncology** and **rare disease** compounds

HAS Healthcare Advanced Synthesis

cerbios

CDMO Portfolio



APIs

APIs up to 100s kg/Batch



HPAPIs

HPAPIs,
from grams to 100s kg/Batch

Anticancer and Linker-Payload

Anticancer,
from 10 to 50 kg/Batch
Up to SafeBridge®
Cat. 3b
Linker-Payload,
from g to 5 kg/Batch
Up to SafeBridge® Cat. 4
(OEL < 10 ng/m³)

ADCs

From development scale
up to 500 L conjugation

HAS Healthcare Advanced Synthesis

cerbios

Research & Development Services

We offer a full range of R&D services to successfully support our partners

- **2 R&D Centers in Biasca and Lugano, with a dedicated Center of Excellence for ADCs at Lugano site**
- **Process development,** optimization and adaptation to HAS/Cerbios commercial plants
- PAR/NOR studies according to classical and/or enhanced approaches (OFAT, QbD/DOE) to identify **Critical Quality Attributes** (CQA) as per Q11
- **Safety Risk Analysis** to guarantee a **robust and safe process** before scaling up at industrial scale
- **Impurity identification & isolation** using cutting edge analytical equipment (preparative HPLC, NMR, MS, UPLC and GC), **impurities synthesis, full characterization**, and supply to our partners
- Impurity fate and purge studies to assess suitable specifications
- **Analytical method development, optimization and validation**
- Analytical method development based on Quality by Design approach

HAS Healthcare Advanced Synthesis

cerbios

Quality Control Services

- **Testing from Starting/Raw materials to final API** using the most common techniques: HPLC, UPLC, LC/MS, IC, GC, HS-GC, GC-MS, GMP NMR, DCS-TGA, Maurice, RP-HPLC, HILIC-HPLC ecc.
- **Continuous improvement** in lab. digitalization: LIMS (Labware), Digital documentation (Trackwise), ELN (Labware).
- State-of-the-Art Facilities and Equipment
- Continuous **Investment in new equipment**/techniques (HPLC/GC, PSD, XRPD, MS detector, SoloVPE®)
- Dedicated and segregated Lab. for HPAPI, Anticancer API, Linker-Payloads and ADCs with safety enclosures
- **Stability chambers for all ICH conditions**
- **Microbiology dedicated laboratory** for Bacterial Endotoxin (LAL) and Microbiological Contamination TVC (TAMC/TYMC)

HAS Healthcare Advanced Synthesis

cerbios

Process Validation & Regulatory Support

Long and well proven experience in supporting our partners throughout the entire product lifecycle

- Discussion of regulatory starting material strategy based on authority requirements
- Full **process risk assessment** based on the outcome of R&D studies
- Definition of the **process control strategy**
- Validation design and documentation (plans, protocols, reports)
- Drug Master File (DMF/ASMF) preparation, filing, and management upon request; support in the **preparation of the relative drug substance sections** (3.2.S) for world-wide registrations
- **30 APIs registered in the last 15 years** in the main geographical areas (EU, US, JP, KR, CN, BR, ROW)
- Relationship with worldwide Regulatory bodies for the managing of Submissions, Deficiencies management, Changes, Annual Report and any other Regulatory request

HAS Healthcare Advanced Synthesis

cerbios

List of Active Projects

2025 PIPELINE

61
Active Projects

32
Active Clients

+4
Advanced Intermediates

50%
Products on the market and NDA submitted

50%
Projects in clinical phase



HAS Healthcare Advanced Synthesis

cerbios

API Manufacturing

Delivering a wide range of clinical & commercial product quantities with a large flexibility in reactor sizes

Reactor range includes **100** to **6300 L**

Temperature range from **-80°C** to **150°C**

Pressure range up to **4 bar**

Stainless Steel, Hastelloy and Glass-lined reactors

Production scale ranges from few grams up to hundreds of kg

HAS Healthcare Advanced Synthesis

cerbios

API Manufacturing

Multipurpose API Production Area

Production

1000, 2500, 4000, 6300 L reactors
Temperature: -80 °C to 140 °C
Pressure: Up to 4 bar
Preparative Chromatographic Equipment
Wet Milling Technology

Isolation

Horizontal peeler centrifuges
Basket centrifuges
Lens filter

Drying

Biconical rotary vacuum dryer (600 L, 4000 L)
Pressure Filter Dryer
Rotavap
Batch Sizes: kgs to 100s of kgs

HAS Healthcare Advanced Synthesis

cerbios

API Manufacturing

Small Scale Production Suite
Reactor Sizes: 100 - 250 L
Temperature: -20 °C to 140 °C
Product Isolation: Centrifuge and Lens Filter
Batch Sizes: Up to 15 kg/batch

Single Scale Campaign Production Suite

Reactor Sizes: 4000 L
Temperature: -15 °C to 140 °C
Product Isolation: Centrifuge and Pressure Filter Dryer
Pressure: Up to 4 bar
Batch Sizes: 10s-100s kg/batch

HAS Healthcare Advanced Synthesis

cerbios

HPAPI Manufacturing

Potent low dose compounds with high therapeutic activity require product handling in containment to protect personnel, environment and the product itself

Reactor range includes from **40 L** up to **4000 L**

Temperature range from **-80°C** to **150°C**

Pressure range up to **4 bar**

Containment: up to OEL **< 30 ng/m³**

Stainless Steel, Hastelloy and Glass-lined reactors

Production scale ranges from few grams up to hundreds of kg

SafeBridge® Category 3 and 4

HAS Healthcare Advanced Synthesis

cerbios

HPAPI Manufacturing

Biasca Site

Small Scale HPAPI Production Suite
Glovebox containment
Reactor Sizes: 100 & 250 L
Temperature: -80 °C to 150 °C
Pressure: Up to 4 bar
Product Isolation: 0.125 m²
Hastelloy pressure-filter-dryer
Batch Sizes: Up to 10 Kg / Batch

Large Scale HPAPI Production Suite

Reactor Size: 4000 L
Temperature: -10°C to 140 °C
Pressure: Up to 4 bar
Product Isolation: Hastelloy Pressure filter dryers (0.8 and 2.5 m²) and Centrifuge
Batch Sizes: 10s – 100s kg / batch

HAS Healthcare Advanced Synthesis

cerbios

HPAPI Manufacturing

Lugano Site

Small Scale HPAPI Production Suite

Reactor Size: From 40 L to 80 L
Temperature: From – 70 °C to 90 °C
Equipment: Flash and preparative chromatography, Photoreaction units, filter and static dryer,
Containment: up to OEL < 10 ng/m³
Reactors: Glass and Hastelloy
Batch Sizes: from 200 g up to 2 kg / Batch

Medium and Large Scale HPAPI Production Suite

Reactor Size: From 400 L to 1000 L
Temperature: From – 70 °C to 90 °C
Equipment: Flash and preparative chromatography, filter dryer
Containment: up to OEL < 30 ng/m³
Reactors: Hastelloy
Batch Sizes: from 5 kg to 35 kg / Batch

HAS Healthcare Advanced Synthesis

cerbios

Anticancer & Linker-payload Manufacturing

Dedicated manufacturing units for manufacturing of clinical and commercial anticancer APIs down to 50 ng/m³and Cytotoxic Linker-Payload for ADCs production to OEL < 10 ng/m³

Reactor range includes from **5 L** up to **1200 L**

Dedicated **R&D** and **Quality** Control Labs

Temperature: **-80 °C** to **150 °C**

Pressure: Up to **4 bar**

7 Dedicated Production Suites with modern glovebox technology

Containment: up to OEL **< 30 ng/m³**

Stainless Steel, Hastelloy and Glass-lined reactors

Production scale ranges from few grams up to hundreds of kg

SafeBridge® Category 4

Anticancer Manufacturing

Biasca Site

Small Scale Production Suite

Reactor Sizes: 20 & 30 L
Product Isolation: 30 L Nutsche Filter & 10 L Tray Dryer
Batch Sizes: Up to ~ 1 Kg / Batch

Mid Scale Production Suite

Reactor Sizes: 250 and 400 L
Product Isolation: 0.125 m²
Hastelloy Pressure Filter-dryer
Batch Sizes: Up to 20 Kg / Batch
Wet Milling

Two Large Scale Production Suites

Reactor Sizes: [630 L, 800 L] & [1000 L, 1200 L]
Product Isolation: 0.3 m² and 0.5 m²
Hastelloy Pressure Filter-dryer
Batch Sizes: Up to 50 Kg / Batch

HAS Healthcare Advanced Synthesis

cerbios

Linker-Payload Manufacturing

Lugano Site

Small to Large-Scale Manufacturing
3 Different cGMP Manufacturing Units

- Reactor Sizes: 5 L, 60 L, 100 L, 200 L
- Equipment: 4-20 L Rotavapors and Static Dryers
- Chromatography: 2 Flash chromatography, up to 5 kg cartridges, 6-90 L/h 100 bar HPLC Prep.
- Chromatography: 110 mm columns, 6-90 L/h 100 bar
- Freeze-Drying: 0.6 m^2 - 7 L, being expanded up to 2 m^2
- Nanofiltration: availability for GMP production
- Containment: up to Category 4 SafeBridge®, OEL < 10 ng/m^3
- Batch Sizes: from 10 g up to 5 kg/ Batch

HAS Healthcare Advanced Synthesis

cerbios

ADC Manufacturing

A combined long-term chemical and biological know-how supported by dedicated suites and investments, positions HAS Group as a CDMO of choice for ADCs.
With our Proveo™ division, we provide a fully integrated end-to-end CDMO service, from CLD and mAbs, up to Linker-Payload, ADC DS and ADC DP, from early clinical stages to commercial supply.

R&D center of excellence in Lugano site

cGMP manufacturing scale from **1 L** up to **500 L**

Single-Use (SU), glass-dedicated and stainless-steel reactors

HAS Healthcare Advanced Synthesis

cerbios

ADC GMP DS manufacturing

ADC cGMP manufacturing from clinical to commercial stages

Cyto and non-cyto linker-payloads

cGMP production units:

- Suite 1:
  up to 200 L conjugation (OEL <10 ng/m^3)
- Suite 2: Under construction; ready 2Q 2026
  Up to **500 L conjugation (OEL <10 ng/m³)**

Capabilities:

- Small scale up to 500 L reaction volume
- Single use or glass reactor vessels
- Single use chromatography
- TFF (single use)
- Bulk filling in bottles or bags
- Integrated Containment system

HAS Healthcare Advanced Synthesis

cerbios

proveo™

A division of Cerbios-Pharma SA

Integrated ADCs Solution

- **Proveo™** is a division of **Cerbios-Pharma SA**
- **Fully integrated ADCs** development and manufacturing services:
  - mAbs
  - Linker-Payloads
  - Conjugation
  - Aseptic Fill & Lyophilization
- **Three world-class players** working together under a single solution



HAS Healthcare Advanced Synthesis

cerbios

PROVEO Integrated Solutions for ADC value chain

- Centralized at one **legal entity (Cerbios-Pharma SA)**

- **Single documentation for**:
  - CDAs
  - Proposal
  - Service Agreement
  - Work Orders
  - Quality Agreement

- **Centralized**
  - Program Management
  - Logistics

PO

Service Agreement

Customer

AGC Biologics

- Cell Line Development
- Protein Production (mAb, fusion, multi-specific)

cerbios
Fostering Value through Innovation®

- Linker-Payload
- Conjugation

medac

CDMO

- Aseptic Fill with Lyophilization

HAS Healthcare Advanced Synthesis

cerbios

Core competences

A combined long-term chemical and biological know-how supported by dedicated suites and investments, positions Cerbios as a CDMO of choice for ADCs.

proveo™

A division of Cerbios-Pharma SA

A unique possibility to develop and manufacture your ADC and all its components: mAb, linker/payload, conjugate, Fill finish DP

Competencies

Traditional stochastic on Lysines and Cysteines

Traditional Site-specific (engineered Cysteines)

Glycan remodelling

Enzymatic (mTG and others)

Peptide driven conjugation

Conjugation expertise with multiple payloads (auristatins, maytansinoids, exatecans, PBDs, chelators, immunomodulators, PEG, etc)

Unique in the CDMO landscape !

Cerbios division PROVEO™ provides a complete service platform for the development and manufacturing of ADCs and each components.

Complete supply chain:

Cell Line Development and mAb manufacturing, Linker-Payload, ADC DS and aseptic fill & lyophilization

HAS Healthcare Advanced Synthesis

cerbios

Core Competencies and Technologies in ADCs

Process Development

- Experience with most types of payloads + conjugation chemistry
- Containment systems (isolators & safetech hoods)
- Conjugation reactors (up to 7 L)
- Preparative chromatography (FPLC, Biotage, HPLC)
- Tangential flow filtration unit
- Continuous flow chemistry systems
- Formulation development
- Analytical method development

HAS Healthcare Advanced Synthesis

cerbios

In-house
GMP analytical capabilities

Instruments

- Bio-inert HPLC (DAD, FLD, ELSD)
- UHPLC
- GC/HS-FID
- Maurice (iCE)
- SoloVPE® System
- Plate reader (abs/lum/fluo)
- Endosafe Charles River
- UV/Vis spectrophotometer
- FT/IR spectrophotometer
- Karl Fischer (volumetric/coulometric)
- Titrators
- DSC
- Optical rotation
- Malvern Mastersizer 3000 (PSD)
- Furnace/oven for ROI/LOD
- Analytical Glove Boxes
- Biosafety cabinets
- Stability chambers ICH Q1A

Characterization analytical capabilities

- LC-MS
- nanoDSF / SLS / DLS (Uncle)
- 400MHz-NMR

Assays

- Protein content (SoloVPE®, Abs280)
- Oligomers HPLC (SE-HPLC)
- Mass (SDS-PAGE, CE-SDS)
- DAR and DAR distrib. by HPLC (HIC, RP, PLRP)
- Charge variants (CEX-HPLC, icIEF)
- Residual free drug (RP-HPLC)
- Residual solvents (GC-HS)
- Bacterial Endotoxin (LAL)
- Microbiological contamination TVC (TAMC/TYMC)
- Potency in vitro cell based* / ELISA

*: in outsourcing

HAS Healthcare Advanced Synthesis

cerbios

Offering the Best CDMO Standards as a Full-service Partner to our Healthcare Clients

Passionate

About tailoring our services to our clients' manufacturing needs

Reliable

Trusted for our quality, reliability, supply chain management and safety

Innovative

Investing to innovate for the future

Sustainable

Committed to improving our environmental impact

HAS Healthcare Advanced Synthesis

cerbios

Thank you

HAS Healthcare Advanced Synthesis

cerbios